{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Thorax&page=54",
    "query": {
      "condition": "Cancer of Thorax",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 4499,
    "total_pages": 450,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Thorax&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Thorax&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:02:22.760Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05416983",
      "title": "Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Non-Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Discussion",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2022-02-17",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05416983"
    },
    {
      "nct_id": "NCT00356122",
      "title": "Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2006-07",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2011-10-17",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00356122"
    },
    {
      "nct_id": "NCT04332653",
      "title": "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Any Advanced Solid Tumors",
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Microsatellite Stable Colorectal Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "NT-I7",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeoImmuneTech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2020-06-10",
      "completion_date": "2025-01-13",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 8,
      "location_summary": "Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04332653"
    },
    {
      "nct_id": "NCT01143545",
      "title": "Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Esophageal Cancer",
        "Malignant Pleural Mesothelioma",
        "Sarcoma",
        "Thymic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Tumor Cell Vaccine (K562)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2010-12-07",
      "completion_date": "2020-02-26",
      "has_results": false,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01143545"
    },
    {
      "nct_id": "NCT03125200",
      "title": "Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Non Small Cell Lung Cancer",
        "GastroEsophageal Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "ADCT-502",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ADC Therapeutics S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-05-18",
      "completion_date": "2018-04-05",
      "has_results": true,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Buffalo, New York • New York, New York + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03125200"
    },
    {
      "nct_id": "NCT02186301",
      "title": "TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Rociletinib Mono-Therapy",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib Mono-Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clovis Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2014-11",
      "completion_date": "2017-06-28",
      "has_results": true,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Burbank, California • Duarte, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186301"
    },
    {
      "nct_id": "NCT00005630",
      "title": "Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ras peptide cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": "2002-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005630"
    },
    {
      "nct_id": "NCT00265200",
      "title": "Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small Cell Lung",
        "Carcinoma, Small Cell Lung",
        "Metastases"
      ],
      "interventions": [
        {
          "name": "zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2005-02",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2018-03-05",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00265200"
    },
    {
      "nct_id": "NCT07090499",
      "title": "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors",
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Advanced Non-Small Cell Lung Cancer",
        "Carcinoma, Non Small Cell Lung",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Head and Neck Cancer",
        "Esophageal Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Esophageal Adenocarcinoma",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "PF-08046876",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Carboplatin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2025-08-20",
      "completion_date": "2029-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 21,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07090499"
    },
    {
      "nct_id": "NCT06097728",
      "title": "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Volrustomig",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 863,
      "start_date": "2023-11-09",
      "completion_date": "2028-11-16",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-19T02:02:22.760Z",
      "location_count": 14,
      "location_summary": "Santa Rosa, California • Aurora, Colorado • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097728"
    }
  ]
}